Atossa Therapeutics reported lower operating expenses for the third quarter and outlined upcoming milestones for its breast cancer and rare-disease programs. It also established contingent value rights tied to a possible future sale of a priority review voucher, giving eligible shareholders a potential share of proceeds if Atossa earns and monetizes one.
The clinical-stage company is developing (Z)-endoxifen for breast cancer and for Duchenne muscular dystrophy and McCune-Albright syndrome. Its stated near-term milestones include regulatory steps for the rare-disease programs and clinical data expected in late 2026 and 2027.
Key details
-
Shareholders received CVRs linked to a possible FDA voucher. Atossa’s board declared one contingent value right for each common share outstanding on October 19, 2026; shares issued after that date also carry a right. The rights remain attached to the shares and will not trade separately unless the board decides to detach them.
-
The potential payment is limited and conditional. CVR holders would collectively receive 25% of net proceeds if Atossa sells or otherwise monetizes the first qualifying FDA priority review voucher awarded to the company. Payments are capped at $50 million in total. Atossa has not received a voucher, and there is no assurance it will receive or monetize one—or that CVR holders will receive a payment.
-
Rare-disease regulatory and trial milestones are expected in 2027. Atossa anticipates FDA clearance of its investigational new drug applications for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome by early 2027. It expects to begin Phase 2 trials in those conditions during 2027.
-
Breast-cancer study updates are also expected. Atossa says the Karisma trial is complete and its results have been finalized in a clinical study report. The company plans to present the results at the San Antonio Breast Cancer Symposium in December 2026 and publicize them afterward. It expects topline results from the Phase 2 EVANGELINE study in the second quarter of 2027; enrollment in that study finished in the second quarter of 2026. Enrollment is also complete in the two reported I-SPY2 study arms combining (Z)-endoxifen with elagolix or abemaciclib, with selected data due at the December symposium.
-
Operating expenses declined. Third-quarter expenses totaled $5.9 million, down from $9.3 million in the same quarter of 2025. For the first nine months of 2026, expenses were $24.5 million, compared with $25.7 million a year earlier.
Atossa’s financial update provides expense figures but no net-loss or cash-balance figures in the information presented here. The CVRs create a potential route for shareholders to share in proceeds from a future voucher transaction, but that value depends on Atossa first earning and monetizing a qualifying voucher.